Annual Meeting Press Program
ASH is pleased to offer credentialed media the following 60-minute press briefings. This year, there will be one virtual briefing before the meeting and several on-site press briefings that will also be livestreamed on the annual meeting virtual platform. All briefings will include thematic overviews, brief presentations by each of the press presenters, and live Q&A. Please note the embargo times indicated.
Please note that all press briefings will take place in the Manchester Grand Hyatt, 4th Floor, Regatta.
Virtual-only briefing
Putting Women & Children First To Optimize Their Hematology Health
Moderator: Ariela Marshall, MD
Briefing time: Wednesday, December 4, 2024, at 9:00 a.m. Pacific time/12:00 p.m. Eastern time (Virtual)
Embargo lift time: Saturday, December 7, 2024, at 7:00 a.m. Pacific time
This briefing showcases studies aimed at optimizing the health and well-being of people from pregnancy, infancy and through childhood and adolescence, including the cost-effectiveness of iron deficiency screening, addressing post-partum hemorrhage, and treating blood cancers and disorders in children.
- 1: Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-Acute Lymphoblastic Leukemia: Results from the Randomized Children’s Oncology Group Study AALL1731
- 681: Safety and Efficacy of Bicistronic CD19/CD22 CAR T Cell Therapy in Childhood B Cell Acute Lymphoblastic Leukemia
- 709: Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
- 796: Post-Partum Hemorrhage in Sub-Saharan Africa: A Prospective, Multi-Faceted Intervention Study in Metropolitan Mozambique
- 277: Sex, Lies, and Iron Deficiency in 2024: Cost-Effectiveness of Screening Ferritin Thresholds for the Treatment of Iron Deficiency in Women of Reproductive Age
On-site and virtual briefings
Food for Thought: How Diet and Lifestyle Affect Hematologic Care
Moderator: Chancellor Donald, MD
Briefing time: Saturday, December 7, 2024, at 7:15 a.m. Pacific time
Embargo lift time: Saturday, December 7, 2024, at 7:15 a.m. Pacific time
These studies highlight how different diet and lifestyle interventions can impact hematologic care, from GLP-1s on venous thromboembolism risk to fiber intake and ketogenic diets for cancer care, and more.
- 701: Glucagon-like Peptide 1 Receptor Agonists Reduce the Risk of Venous Thromboembolism in Patients with Diabetes Irrespective of Obesity: A Propensity Score-Matched Multicenter Database Analysis
- 259: Increased Fiber Intake Results in Better Overall Survival and Lower GI-aGVHD in Allo-HCT Recipients and Pre-Clinical Gvhd Models
- 671: A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma
- 4597: Association between Smoking Intensity, Genetic Mutations, and Disease Progression in Myelodysplastic Syndromes
- 4: Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate
Reading Up on the Classics: Treating Not-So-Benign Hematology Conditions
Moderator: Charles Abrams, MD
Briefing time: Saturday, December 7 at 8:30 a.m. Pacific time
Embargo lift time: Saturday, December 7 at 8:30 a.m. Pacific time
Together, these studies highlight novel methods and treatments in classical hematology, including the treatment of pain crises for people living with sickle cell disease, hydroxyurea for a genetic sickle cell variant, oral inhibitors for immune thrombocytopenia, and more.
- 802: Fertility Preservation Outcomes for People with Ovaries and Sickle Cell Anemia: A Multi-Center Study
- 5: Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3)
- 179: Etavopivat Reduces Incidence of Vaso-Occlusive Crises in Patients with Sickle Cell Disease: HIBISCUS Trial Phase 2 Results through 52 Weeks
- 3: Double-Blind, Placebo-Controlled Randomized Controlled Trial of Hydroxyurea for HbSC: Results of the Prospective Identification of Variables As Outcomes for Treatment (PIVOT) Trial
- 513: Initial Results from the BEACON Clinical Study: A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients with Sickle Cell Disease with Severe Vaso-Occlusive Crises
Diagnosing and Treating Blood Cancers and "Almost Cancers"
Moderator: Surbhi Sidana, MD
Briefing time: Sunday, December 8, 2024, at 8:00 a.m. Pacific time
Embargo lift time: Sunday, December 8, 2024, at 8:00 a.m. Pacific time
This briefing features advances in malignant hematology, including clinical trial results for smoldering multiple myeloma and leukemia, as well as how socioeconomic factors impact allogeneic cell transplant outcomes, and more.
- 773: Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study
- 1009: Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial
- 883: Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1
- 943: Elevated Clonal Hematopoiesis in Environmentally Exposed Responders Has Distinct Age-Related Patterns and Relies on IL1RAP for Clonal Expansion
- 6: Impact of Socioeconomic Factors on Access to and Outcomes of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Acute Myeloid Leukemia (AML): A Multi-Center Observational Study
Late-Breaking Abstracts Press Briefing
Moderator:Mikkael Sekeres, MD
Briefing time: Monday, Dec. 9, 2024 at 8:00 a.m. Pacific Time
Embargo lift time: Tuesday, Dec. 10, 2024 at 7:30 a.m. Pacific time
This briefing highlights a selection of late-breaking abstracts.
- LBA-1: Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)
- LBA-6: Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial
- LBA-5: Outcome of Cerebral Vasculopathy and Cognitive Performances 10 Years Post-Enrollment in the Drepagreffe Trial Comparing Allogeneic Stem Cell Transplantation to Standard-Care in Children with Sickle Cell Anemia and History of Abnormal Cerebral Velocities
- LBA-4: Andean Enriched NFKB1 Haplotype Reduces Inflammation and Improves Response to Ropeginterferon Alfa-2b in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
Help ASH Build an Inclusive Hematology Community!
ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.
How Can You Help?
Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!
Update Access to Demographic Information Learn About Our Mission